



08-02-02

1642

Patent Docket #1467R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of Mark Sliwkowski (as amended) Serial No.: 09/602,812 Filed: June 23, 2000 For: Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies	Group Art Unit: 1642 Examiner: J. Hunt CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: U.S. Patent and Trademark Office, Washington, D.C. 20231-9999 Express Mail Label No. EV 673 722 636 US August 11, 2002 Wendy M. Lee
---	--

AUG 07 2002

TECH CENTER 1600/2900

1513
60
8/6/02

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Responsive to the Office Action mailed 4/1/02, reconsideration of the present application is respectfully requested in view of the following amendments and remarks. A request for a one month extension of time and the fee therefor are filed with this amendment.

IN THE SPECIFICATION:

Please replace the paragraph starting on page 1, line 27 with the following:

B1
The second member of the ErbB family, p185^{neu}, was originally identified as the product of the transforming gene from neuroblastomas of chemically treated rats. The activated form of the *neu* proto-oncogene results from a point mutation (valine to glutamic acid) in the transmembrane region of the encoded protein. Amplification of the human homolog of *neu* is observed in breast and ovarian cancers and correlates with a poor prognosis (Slamon et al., *Science*, 235:177-182 (1987); Slamon et al., *Science*, 244:707-712 (1989); and US Pat No. 4,968,603). To date, no point mutation analogous to that in the *neu* proto-oncogene has been